ABUS
Arbutus Biopharma Corporation
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-07-2018 after market close | 08-02-2018 after market close | 05-03-2018 | 03-14-2018 | 11-02-2017 after market close | 08-03-2017 after market close | 05-04-2017 after market close | |
|---|---|---|---|---|---|---|---|
| Actual EPS | -0.3 | -0.44 | -0.36 | -0.9 | -0.17 | -0.28 | -0.34 |
| Consensus EPS | -0.39 | -0.35 | -0.38 | -0.39 | -0.38 | -0.35 | -0.3 |
| Estimated EPS | -0.39 | -0.35 | -0.38 | -0.39 | -0.38 | -0.35 | -0.3 |
| Number of Estimates | 3 | 3 | 3 | 2 | 3 | 3 | 3 |
| EPS Surprise | $0.09 | -$0.09 | $0.02 | -$0.51 | $0.21 | $0.07 | -$0.04 |
Stats
Summary
Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
Market Cap: 292 Million
Primary Exchange: Nasdaq Global Select
Website: http://www.arbutusbio.com
Shares Outstanding: 55.6 Million
Float: 51 Million
Dividend: 0.0 (0.0%)
Beta: 1.128171
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 705 Thousand
Ethical Flags
Longest drawdown: 1245 trading days
From: 2014-03-11 To: 2019-02-20
Lowest Point:
Arbutus Biopharma Corp's (ABUS) CEO Mark Murray on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-07 20:41:08:000
Arbutus Biopharma Corp (ABUS) Q3 2018 Earnings Conference Call November 7, 2018 04:30 pm ET Executives Pam Murphy - IR Mark Murray - President and CEO Mike Sofia - CSO David Hastings - CFO Analysts Liisa Bayko - JMP Securities Katherine Xu - William Blair Keay Nakae -… read more...
Arbutus Biopharma Corp's (ABUS) CEO Mark Murray on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-07 20:41:08:000
Arbutus Biopharma Corp (ABUS) Q3 2018 Earnings Conference Call November 7, 2018 04:30 pm ET Executives Pam Murphy - IR Mark Murray - President and CEO Mike Sofia - CSO David Hastings - CFO Analysts Liisa Bayko - JMP Securities Katherine Xu - William Blair Keay Nakae -… read more...
Arbutus Biopharma Corp's (ABUS) CEO Mark Murray on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-07 20:41:08:000
Arbutus Biopharma Corp (ABUS) Q3 2018 Earnings Conference Call November 7, 2018 04:30 pm ET Executives Pam Murphy - IR Mark Murray - President and CEO Mike Sofia - CSO David Hastings - CFO Analysts Liisa Bayko - JMP Securities Katherine Xu - William Blair Keay Nakae -… read more...
Arbutus Biopharma misses by $0.08
via: SeekingAlpha at 2018-11-07 16:04:12:000
Arbutus Biopharma (NASDAQ: ABUS ): Q3 GAAP EPS of -$0.49 misses by $0.08 . Revenue of $1.6M (-76.8% Y/Y) Press Release More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, read more...
Assembly Biosciences: A Horseman Of The HBV Core-Pocalypse?
via: SeekingAlpha at 2018-10-19 11:23:09:000
Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi… read more...
Assembly Biosciences: A Horseman Of The HBV Core-Pocalypse?
via: SeekingAlpha at 2018-10-19 11:23:09:000
Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi… read more...
Assembly Biosciences: A Horseman Of The HBV Core-Pocalypse?
via: SeekingAlpha at 2018-10-19 11:23:09:000
Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi… read more...
Assembly Biosciences: A Horseman Of The HBV Core-Pocalypse?
via: SeekingAlpha at 2018-10-19 11:23:09:000
Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi… read more...
Assembly Biosciences: A Horseman Of The HBV Core-Pocalypse?
via: SeekingAlpha at 2018-10-19 11:23:09:000
Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-16 07:49:45:000
Abbott (NYSE: ABT ) initiated with Overweight rating and $80 (16% upside) price target at Barclays. More news on: Abbott Laboratories, Arbutus Biopharma Corp, Avanos Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-16 07:49:45:000
Abbott (NYSE: ABT ) initiated with Overweight rating and $80 (16% upside) price target at Barclays. More news on: Abbott Laboratories, Arbutus Biopharma Corp, Avanos Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-16 07:49:45:000
Abbott (NYSE: ABT ) initiated with Overweight rating and $80 (16% upside) price target at Barclays. More news on: Abbott Laboratories, Arbutus Biopharma Corp, Avanos Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-15 07:30:48:000
Argenx (NASDAQ: ARGX ) initiated with Outperform rating and $110 (51% upside) price target at Evercore ISI. More news on: Argenx SE, Elanco, KalVista Pharmaceticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Weekly market movement wrap
via: SeekingAlpha at 2018-10-13 17:35:40:000
See a week over week comparison below for the following indices, equities, commodities, bonds and currencies. More news on: Youngevity International, Inc., CorMedix Inc., Pyxus International, Inc., Top stock market news, Quick stock ideas, News on the U.S. economy, Financial stocks news, H… read more...
Weekly market movement wrap
via: SeekingAlpha at 2018-10-13 17:35:40:000
See a week over week comparison below for the following indices, equities, commodities, bonds and currencies. More news on: Youngevity International, Inc., CorMedix Inc., Pyxus International, Inc., Top stock market news, Quick stock ideas, News on the U.S. economy, Financial stocks news, H… read more...
Arbutus Bio down 24% on delay of early-stage study of HBV candidate AB-452
via: SeekingAlpha at 2018-10-09 11:54:04:000
Arbutus Biopharma ( ABUS -24.1% ) is down on almost triple normal volume in apparent reaction to its announced update on its hepatitis B virus (HBV) programs that includes a delay in the start of a Phase 1 clinical trial evaluating RNA-destabilizer AB-452 in order to allow for more tim… read more...
Arbutus Bio down 24% on delay of early-stage study of HBV candidate AB-452
via: SeekingAlpha at 2018-10-09 11:54:04:000
Arbutus Biopharma ( ABUS -24.1% ) is down on almost triple normal volume in apparent reaction to its announced update on its hepatitis B virus (HBV) programs that includes a delay in the start of a Phase 1 clinical trial evaluating RNA-destabilizer AB-452 in order to allow for more tim… read more...
Arbutus Bio down 24% on delay of early-stage study of HBV candidate AB-452
via: SeekingAlpha at 2018-10-09 11:54:04:000
Arbutus Biopharma ( ABUS -24.1% ) is down on almost triple normal volume in apparent reaction to its announced update on its hepatitis B virus (HBV) programs that includes a delay in the start of a Phase 1 clinical trial evaluating RNA-destabilizer AB-452 in order to allow for more tim… read more...
Arbutus Biopharma: The Good, The Bad, And The Ugly
via: SeekingAlpha at 2018-10-09 11:25:50:000
Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve… read more...
Arbutus Biopharma: The Good, The Bad, And The Ugly
via: SeekingAlpha at 2018-10-09 11:25:50:000
Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve… read more...
Arbutus Biopharma: The Good, The Bad, And The Ugly
via: SeekingAlpha at 2018-10-09 11:25:50:000
Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
More Volatility Ahead For Arbutus Biopharma
via: SeekingAlpha at 2018-08-17 16:06:34:000
Invest only if you would be comfortable owning a stock even if you had no way of knowing its daily share price. - Benjamin Graham, The Intelligent Investor My initial coverage of Arbutus ( ABUS ) cautioned longs of a near-term 20-30% price decline, but underlined the long-term valu… read more...
More Volatility Ahead For Arbutus Biopharma
via: SeekingAlpha at 2018-08-17 16:06:34:000
Invest only if you would be comfortable owning a stock even if you had no way of knowing its daily share price. - Benjamin Graham, The Intelligent Investor My initial coverage of Arbutus ( ABUS ) cautioned longs of a near-term 20-30% price decline, but underlined the long-term valu… read more...
More Volatility Ahead For Arbutus Biopharma
via: SeekingAlpha at 2018-08-17 16:06:34:000
Invest only if you would be comfortable owning a stock even if you had no way of knowing its daily share price. - Benjamin Graham, The Intelligent Investor My initial coverage of Arbutus ( ABUS ) cautioned longs of a near-term 20-30% price decline, but underlined the long-term valu… read more...
More Volatility Ahead For Arbutus Biopharma
via: SeekingAlpha at 2018-08-17 16:06:34:000
Invest only if you would be comfortable owning a stock even if you had no way of knowing its daily share price. - Benjamin Graham, The Intelligent Investor My initial coverage of Arbutus ( ABUS ) cautioned longs of a near-term 20-30% price decline, but underlined the long-term valu… read more...
More Volatility Ahead For Arbutus Biopharma
via: SeekingAlpha at 2018-08-17 16:06:34:000
Invest only if you would be comfortable owning a stock even if you had no way of knowing its daily share price. - Benjamin Graham, The Intelligent Investor My initial coverage of Arbutus ( ABUS ) cautioned longs of a near-term 20-30% price decline, but underlined the long-term valu… read more...
Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making History
via: SeekingAlpha at 2018-08-13 02:14:28:000
Recently, Alnylam Pharmaceuticals ( ALNY ) announced that it had received FDA approval for its drug Patisiran . This is the first of many approvals, because the EMA is also reviewing the drug for treating the same disease hereditary ATTR ((hATTR)) amyloidosis. The company has a pipeline f… read more...
Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making History
via: SeekingAlpha at 2018-08-13 02:14:28:000
Recently, Alnylam Pharmaceuticals ( ALNY ) announced that it had received FDA approval for its drug Patisiran . This is the first of many approvals, because the EMA is also reviewing the drug for treating the same disease hereditary ATTR ((hATTR)) amyloidosis. The company has a pipeline f… read more...
Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making History
via: SeekingAlpha at 2018-08-13 02:14:28:000
Recently, Alnylam Pharmaceuticals ( ALNY ) announced that it had received FDA approval for its drug Patisiran . This is the first of many approvals, because the EMA is also reviewing the drug for treating the same disease hereditary ATTR ((hATTR)) amyloidosis. The company has a pipeline f… read more...
Midday Gainers / Losers (08/03/2018)
via: SeekingAlpha at 2018-08-03 12:50:15:000
Gainers: WMLP +78% . NGVC +30% . OXBR +29% . PXLW +28% . MED +25% . HQCL +25% . UEIC +24% . TACT +21% . CTRL +20% . GPRO +20% . More news on: Westmoreland Resource Partners, LP, Natural Grocers, Oxbridge Re Holdings Limited, Stocks on the move, , Read m… read more...
Midday Gainers / Losers (08/03/2018)
via: SeekingAlpha at 2018-08-03 12:50:15:000
Gainers: WMLP +78% . NGVC +30% . OXBR +29% . PXLW +28% . MED +25% . HQCL +25% . UEIC +24% . TACT +21% . CTRL +20% . GPRO +20% . More news on: Westmoreland Resource Partners, LP, Natural Grocers, Oxbridge Re Holdings Limited, Stocks on the move, , Read m… read more...
Midday Gainers / Losers (08/03/2018)
via: SeekingAlpha at 2018-08-03 12:50:15:000
Gainers: WMLP +78% . NGVC +30% . OXBR +29% . PXLW +28% . MED +25% . HQCL +25% . UEIC +24% . TACT +21% . CTRL +20% . GPRO +20% . More news on: Westmoreland Resource Partners, LP, Natural Grocers, Oxbridge Re Holdings Limited, Stocks on the move, , Read m… read more...
Midday Gainers / Losers (08/03/2018)
via: SeekingAlpha at 2018-08-03 12:50:15:000
Gainers: WMLP +78% . NGVC +30% . OXBR +29% . PXLW +28% . MED +25% . HQCL +25% . UEIC +24% . TACT +21% . CTRL +20% . GPRO +20% . More news on: Westmoreland Resource Partners, LP, Natural Grocers, Oxbridge Re Holdings Limited, Stocks on the move, , Read m… read more...
Midday Gainers / Losers (08/03/2018)
via: SeekingAlpha at 2018-08-03 12:50:15:000
Gainers: WMLP +78% . NGVC +30% . OXBR +29% . PXLW +28% . MED +25% . HQCL +25% . UEIC +24% . TACT +21% . CTRL +20% . GPRO +20% . More news on: Westmoreland Resource Partners, LP, Natural Grocers, Oxbridge Re Holdings Limited, Stocks on the move, , Read m… read more...
Arbutus down 16% after Q2 report
via: SeekingAlpha at 2018-08-03 10:22:01:000
Arbutus Biopharma ( ABUS -15.8% ) slumps in early trade on average volume. Yesterday after the close it reported Q2 results . Highlights: More news on: Arbutus Biopharma Corp, Healthcare stocks news, Stocks on the move, Read more … read more...
Arbutus down 16% after Q2 report
via: SeekingAlpha at 2018-08-03 10:22:01:000
Arbutus Biopharma ( ABUS -15.8% ) slumps in early trade on average volume. Yesterday after the close it reported Q2 results . Highlights: More news on: Arbutus Biopharma Corp, Healthcare stocks news, Stocks on the move, Read more … read more...
Arbutus down 16% after Q2 report
via: SeekingAlpha at 2018-08-03 10:22:01:000
Arbutus Biopharma ( ABUS -15.8% ) slumps in early trade on average volume. Yesterday after the close it reported Q2 results . Highlights: More news on: Arbutus Biopharma Corp, Healthcare stocks news, Stocks on the move, Read more … read more...
Arbutus down 16% after Q2 report
via: SeekingAlpha at 2018-08-03 10:22:01:000
Arbutus Biopharma ( ABUS -15.8% ) slumps in early trade on average volume. Yesterday after the close it reported Q2 results . Highlights: More news on: Arbutus Biopharma Corp, Healthcare stocks news, Stocks on the move, Read more … read more...
Arbutus down 16% after Q2 report
via: SeekingAlpha at 2018-08-03 10:22:01:000
Arbutus Biopharma ( ABUS -15.8% ) slumps in early trade on average volume. Yesterday after the close it reported Q2 results . Highlights: More news on: Arbutus Biopharma Corp, Healthcare stocks news, Stocks on the move, Read more … read more...
Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 00:32:19:000
Arbutus Biopharma Corp (ABUS) Q2 2018 Earnings Conference Call August 2, 2018, 4:30 PM ET Executives Pam Murphy - IR Mark Murray - CEO Michael Sofia - CSO William Symonds - Chief Development Officer David Hastings - CFO Koert VandenEnden - Chief Accounting Officer Analys… read more...
Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 00:32:19:000
Arbutus Biopharma Corp (ABUS) Q2 2018 Earnings Conference Call August 2, 2018, 4:30 PM ET Executives Pam Murphy - IR Mark Murray - CEO Michael Sofia - CSO William Symonds - Chief Development Officer David Hastings - CFO Koert VandenEnden - Chief Accounting Officer Analys… read more...
Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 00:32:19:000
Arbutus Biopharma Corp (ABUS) Q2 2018 Earnings Conference Call August 2, 2018, 4:30 PM ET Executives Pam Murphy - IR Mark Murray - CEO Michael Sofia - CSO William Symonds - Chief Development Officer David Hastings - CFO Koert VandenEnden - Chief Accounting Officer Analys… read more...
Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 00:32:19:000
Arbutus Biopharma Corp (ABUS) Q2 2018 Earnings Conference Call August 2, 2018, 4:30 PM ET Executives Pam Murphy - IR Mark Murray - CEO Michael Sofia - CSO William Symonds - Chief Development Officer David Hastings - CFO Koert VandenEnden - Chief Accounting Officer Analys… read more...
Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-03 00:32:19:000
Arbutus Biopharma Corp (ABUS) Q2 2018 Earnings Conference Call August 2, 2018, 4:30 PM ET Executives Pam Murphy - IR Mark Murray - CEO Michael Sofia - CSO William Symonds - Chief Development Officer David Hastings - CFO Koert VandenEnden - Chief Accounting Officer Analys… read more...
Arbutus Biopharma reports Q2 results
via: SeekingAlpha at 2018-08-02 16:02:28:000
Arbutus Biopharma (NASDAQ: ABUS ): Q2 EPS of -$0.44 More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Medical Stock Investing: 2018 Update
via: SeekingAlpha at 2018-08-02 09:37:22:000
Given that we are just past the midpoint, I thought it would be a good time to review and update my 2018 forecast and stock picks. As I suggested, 2018 has turned out to be a stockpicker's year. The fundamentals of the US healthcare industry remain strong, as demographics, chronic disease prev… read more...
Arbutus: An Extremely Promising RNAi Innovator Hitting Its Growth Inflection
via: SeekingAlpha at 2018-07-19 05:25:01:000
Before you do invest anything in stocks, you ought to consider buying a house, since a house, after all, is the one good investment that almost everyone manages to make. Im sure there are exceptions, such as houses built over sinkholes and houses in fancy neighborhoods that take a div… read more...
Arbutus: An Extremely Promising RNAi Innovator Hitting Its Growth Inflection
via: SeekingAlpha at 2018-07-19 05:25:01:000
Before you do invest anything in stocks, you ought to consider buying a house, since a house, after all, is the one good investment that almost everyone manages to make. Im sure there are exceptions, such as houses built over sinkholes and houses in fancy neighborhoods that take a div… read more...
Arbutus: An Extremely Promising RNAi Innovator Hitting Its Growth Inflection
via: SeekingAlpha at 2018-07-19 05:25:01:000
Before you do invest anything in stocks, you ought to consider buying a house, since a house, after all, is the one good investment that almost everyone manages to make. Im sure there are exceptions, such as houses built over sinkholes and houses in fancy neighborhoods that take a div… read more...
Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun
via: SeekingAlpha at 2018-07-18 16:03:11:000
While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...
Arbutus Biopharma: Run Up Continues, Catalyst In Focus
via: SeekingAlpha at 2018-07-09 15:35:29:000
Shares of Arbutus Biopharma ( ABUS ) have risen by more than 175% since my article from April of last year pointed out that there were "2 ways for shareholders to win." The stock price has increased by 20% since my update piece from last October. Chart Figure 1: ABUS daily adv… read more...
Arbutus Biopharma: Run Up Continues, Catalyst In Focus
via: SeekingAlpha at 2018-07-09 15:35:29:000
Shares of Arbutus Biopharma ( ABUS ) have risen by more than 175% since my article from April of last year pointed out that there were "2 ways for shareholders to win." The stock price has increased by 20% since my update piece from last October. Chart Figure 1: ABUS daily adv… read more...
Arbutus Biopharma: Run Up Continues, Catalyst In Focus
via: SeekingAlpha at 2018-07-09 15:35:29:000
Shares of Arbutus Biopharma ( ABUS ) have risen by more than 175% since my article from April of last year pointed out that there were "2 ways for shareholders to win." The stock price has increased by 20% since my update piece from last October. Chart Figure 1: ABUS daily adv… read more...
Arbutus Biopharma: The Next Big Breakout Biotech?
via: SeekingAlpha at 2018-06-22 10:18:28:000
Introduction Arbutus Biopharma (ABUS) is a biotech company with a market capitalization of $387 million. Arbutus focuses on developing treatments for HBV. The company has three different products in development targeting different steps in the viruses' life-cycle. Arbutus' lead compound ARB-… read more...
Arbutus Biopharma: The Next Big Breakout Biotech?
via: SeekingAlpha at 2018-06-22 10:18:28:000
Introduction Arbutus Biopharma (ABUS) is a biotech company with a market capitalization of $387 million. Arbutus focuses on developing treatments for HBV. The company has three different products in development targeting different steps in the viruses' life-cycle. Arbutus' lead compound ARB-… read more...
Arbutus Biopharma: The Next Big Breakout Biotech?
via: SeekingAlpha at 2018-06-22 10:18:28:000
Introduction Arbutus Biopharma (ABUS) is a biotech company with a market capitalization of $387 million. Arbutus focuses on developing treatments for HBV. The company has three different products in development targeting different steps in the viruses' life-cycle. Arbutus' lead compound ARB-… read more...
Arbutus Biopharma: The Next Big Breakout Biotech?
via: SeekingAlpha at 2018-06-22 10:18:28:000
Introduction Arbutus Biopharma (ABUS) is a biotech company with a market capitalization of $387 million. Arbutus focuses on developing treatments for HBV. The company has three different products in development targeting different steps in the viruses' life-cycle. Arbutus' lead compound ARB-… read more...
Arbutus Biopharma: The Next Big Breakout Biotech?
via: SeekingAlpha at 2018-06-22 10:18:28:000
Introduction Arbutus Biopharma (ABUS) is a biotech company with a market capitalization of $387 million. Arbutus focuses on developing treatments for HBV. The company has three different products in development targeting different steps in the viruses' life-cycle. Arbutus' lead compound ARB-… read more...
Does Gilead's Have A HBV Blockbuster Drug In The Works?
via: SeekingAlpha at 2018-06-19 13:14:32:000
Introduction The focus of this article will be on Gileads (NASDAQ: GILD ) HBV treatments and their future prospects. I will delve into the biology of HBV and why it is so difficult to cure. I will discuss how Viread and Vemildy are not game changers in the HBV field but provide a … read more...
Does Gilead's Have A HBV Blockbuster Drug In The Works?
via: SeekingAlpha at 2018-06-19 13:14:32:000
Introduction The focus of this article will be on Gileads (NASDAQ: GILD ) HBV treatments and their future prospects. I will delve into the biology of HBV and why it is so difficult to cure. I will discuss how Viread and Vemildy are not game changers in the HBV field but provide a … read more...
Does Gilead's Have A HBV Blockbuster Drug In The Works?
via: SeekingAlpha at 2018-06-19 13:14:32:000
Introduction The focus of this article will be on Gileads (NASDAQ: GILD ) HBV treatments and their future prospects. I will delve into the biology of HBV and why it is so difficult to cure. I will discuss how Viread and Vemildy are not game changers in the HBV field but provide a … read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2018 Update
via: SeekingAlpha at 2018-05-27 06:18:24:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2018 Update
via: SeekingAlpha at 2018-05-27 06:18:24:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2018 Update
via: SeekingAlpha at 2018-05-27 06:18:24:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2018 Update
via: SeekingAlpha at 2018-05-27 06:18:24:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Arbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-06 13:15:06:000
Arbutus Biopharma Corp. (ABUS) Q1 2018 Earnings Conference Call May 03, 2018 04:30 PM ET Executives Tiffany Tolmie - Manager, Investor Relations Mark Murray - Chief Executive Officer William Symonds - Chief Development Officer Koert VandenEnden - Interim CFO Analysts Kath… read more...
Arbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-06 13:15:06:000
Arbutus Biopharma Corp. (ABUS) Q1 2018 Earnings Conference Call May 03, 2018 04:30 PM ET Executives Tiffany Tolmie - Manager, Investor Relations Mark Murray - Chief Executive Officer William Symonds - Chief Development Officer Koert VandenEnden - Interim CFO Analysts Kath… read more...
Arbutus Biopharma beats by $0.03, beats on revenue
via: SeekingAlpha at 2018-05-03 16:14:55:000
Arbutus Biopharma (NASDAQ: ABUS ): Q1 EPS of -$0.36 beats by $0.03 . More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Arbutus Biopharma beats by $0.03, beats on revenue
via: SeekingAlpha at 2018-05-03 16:14:55:000
Arbutus Biopharma (NASDAQ: ABUS ): Q1 EPS of -$0.36 beats by $0.03 . More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Eidos Therapeutics commences mid-stage study of lead drug in ATTR
via: SeekingAlpha at 2018-05-03 09:55:05:000
Privately held Eidos Therapeutics announces that the first patient has been dosed in a Phase 2 clinical trial assessing lead candidate AG10 in patients with symptomatic transthyretin amyloidosis (ATTR) cardiomyopathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals… read more...
Eidos Therapeutics commences mid-stage study of lead drug in ATTR
via: SeekingAlpha at 2018-05-03 09:55:05:000
Privately held Eidos Therapeutics announces that the first patient has been dosed in a Phase 2 clinical trial assessing lead candidate AG10 in patients with symptomatic transthyretin amyloidosis (ATTR) cardiomyopathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals… read more...
RNAi For Hepatitis B - A False Hope For A Cure?
via: SeekingAlpha at 2018-04-06 14:59:28:000
Editor's note: Seeking Alpha is proud to welcome BZ Equity Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Hepat… read more...
RNAi For Hepatitis B - A False Hope For A Cure?
via: SeekingAlpha at 2018-04-06 14:59:28:000
Editor's note: Seeking Alpha is proud to welcome BZ Equity Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Hepat… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-03-19 08:47:23:000
Synlogic (NASDAQ: SYBX ) initiated with Buy rating and $20 (104% upside) price target at H.C. Wainwright. More news on: Synlogic, Inc., Arbutus Biopharma Corp, Ignyta, Inc., Healthcare stocks news, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-03-19 08:47:23:000
Synlogic (NASDAQ: SYBX ) initiated with Buy rating and $20 (104% upside) price target at H.C. Wainwright. More news on: Synlogic, Inc., Arbutus Biopharma Corp, Ignyta, Inc., Healthcare stocks news, , Read more … read more...
Arbutus Biopharma's (ABUS) CEO Mark Murray on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-03-14 21:39:03:000
Arbutus Biopharma Corp. (ABUS) Q4 2017 Results Earnings Conference Call March 14, 2018, 04:30 PM ET Executives Tiffany Tolmie - Manager, Investor Relations Mark Murray - Chief Executive Officer Mike Sofia - Chief Scientific Officer Bill Symonds - Chief Development Officer Koe… read more...
Arbutus Biopharma's (ABUS) CEO Mark Murray on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-03-14 21:39:03:000
Arbutus Biopharma Corp. (ABUS) Q4 2017 Results Earnings Conference Call March 14, 2018, 04:30 PM ET Executives Tiffany Tolmie - Manager, Investor Relations Mark Murray - Chief Executive Officer Mike Sofia - Chief Scientific Officer Bill Symonds - Chief Development Officer Koe… read more...
Arbutus to launch mid-stage study of HBV triplet therapy in coming weeks
via: SeekingAlpha at 2018-03-14 16:42:05:000
Arbutus Biopharma (NASDAQ: ABUS ) announces 2018 expected milestones: More news on: Arbutus Biopharma Corp, Healthcare stocks news, Earnings news and commentary, Read more … read more...
Arbutus to launch mid-stage study of HBV triplet therapy in coming weeks
via: SeekingAlpha at 2018-03-14 16:42:05:000
Arbutus Biopharma (NASDAQ: ABUS ) announces 2018 expected milestones: More news on: Arbutus Biopharma Corp, Healthcare stocks news, Earnings news and commentary, Read more … read more...
Arbutus Biopharma beats by $0.22, beats on revenue
via: SeekingAlpha at 2018-03-14 16:03:01:000
Arbutus Biopharma (NASDAQ: ABUS ): Q4 EPS of -$1.09 beats by $0.22 . Revenue of $10.7M (+613.3% Y/Y) beats by $3.27M . Press Release More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, read more...
Arbutus Biopharma beats by $0.22, beats on revenue
via: SeekingAlpha at 2018-03-14 16:03:01:000
Arbutus Biopharma (NASDAQ: ABUS ): Q4 EPS of -$1.09 beats by $0.22 . Revenue of $10.7M (+613.3% Y/Y) beats by $3.27M . Press Release More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2017 Update
via: SeekingAlpha at 2018-02-22 11:53:40:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's US stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 02/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global … read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2017 Update
via: SeekingAlpha at 2018-02-22 11:53:40:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's US stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 02/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global … read more...
Healthcare: The 'Week That Was' Was Good
via: SeekingAlpha at 2018-01-17 12:08:19:000
Healthcare stocks performed well last week, and despite today's decline, tomorrow looks positive, given the rumor that Celgene ( CELG ) is in talks to acquire Juno ( JUNO ). The latter stock is up sharply in the aftermarket. It is important to realize that worldwide sales of oncology drugs exc… read more...
Healthcare: The 'Week That Was' Was Good
via: SeekingAlpha at 2018-01-17 12:08:19:000
Healthcare stocks performed well last week, and despite today's decline, tomorrow looks positive, given the rumor that Celgene ( CELG ) is in talks to acquire Juno ( JUNO ). The latter stock is up sharply in the aftermarket. It is important to realize that worldwide sales of oncology drugs exc… read more...
Healthcare: The 'Week That Was' Was Good
via: SeekingAlpha at 2018-01-17 12:08:19:000
Healthcare stocks performed well last week, and despite today's decline, tomorrow looks positive, given the rumor that Celgene ( CELG ) is in talks to acquire Juno ( JUNO ). The latter stock is up sharply in the aftermarket. It is important to realize that worldwide sales of oncology drugs exc… read more...
Healthcare: The 'Week That Was' Was Good
via: SeekingAlpha at 2018-01-17 12:08:19:000
Healthcare stocks performed well last week, and despite today's decline, tomorrow looks positive, given the rumor that Celgene ( CELG ) is in talks to acquire Juno ( JUNO ). The latter stock is up sharply in the aftermarket. It is important to realize that worldwide sales of oncology drugs exc… read more...
Healthcare: The 'Week That Was' Was Good
via: SeekingAlpha at 2018-01-17 12:08:19:000
Healthcare stocks performed well last week, and despite today's decline, tomorrow looks positive, given the rumor that Celgene ( CELG ) is in talks to acquire Juno ( JUNO ). The latter stock is up sharply in the aftermarket. It is important to realize that worldwide sales of oncology drugs exc… read more...
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
via: SeekingAlpha at 2018-01-09 11:02:20:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
via: SeekingAlpha at 2018-01-09 11:02:20:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
via: SeekingAlpha at 2018-01-09 11:02:20:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
via: SeekingAlpha at 2018-01-09 11:02:20:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
via: SeekingAlpha at 2018-01-09 11:02:20:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-05 08:34:15:000
AmerisourceBergen (NYSE: ABC ) initiated with Outperform rating and $105 (12% upside) price target by Evercore ISI. More news on: AmerisourceBergen Corporation, Arbutus Biopharma Corp, AxoGen, Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-05 08:34:15:000
AmerisourceBergen (NYSE: ABC ) initiated with Outperform rating and $105 (12% upside) price target by Evercore ISI. More news on: AmerisourceBergen Corporation, Arbutus Biopharma Corp, AxoGen, Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-05 08:34:15:000
AmerisourceBergen (NYSE: ABC ) initiated with Outperform rating and $105 (12% upside) price target by Evercore ISI. More news on: AmerisourceBergen Corporation, Arbutus Biopharma Corp, AxoGen, Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-05 08:34:15:000
AmerisourceBergen (NYSE: ABC ) initiated with Outperform rating and $105 (12% upside) price target by Evercore ISI. More news on: AmerisourceBergen Corporation, Arbutus Biopharma Corp, AxoGen, Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-05 08:34:15:000
AmerisourceBergen (NYSE: ABC ) initiated with Outperform rating and $105 (12% upside) price target by Evercore ISI. More news on: AmerisourceBergen Corporation, Arbutus Biopharma Corp, AxoGen, Inc., Healthcare stocks news, Read more … read more...
Going Out On A Limb: Expectations For Healthcare Stocks In January
via: SeekingAlpha at 2017-12-22 08:53:57:000
In January 2016, the biopharmaceutical stocks declined sharply, and the relevant indices did not fully recover for nearly 18 months. In fact, the IBB now stands 5% below the level at which it closed out 2015. As I discussed in my 12/1/2017 article, we are on the verge of another great era in… read more...
Going Out On A Limb: Expectations For Healthcare Stocks In January
via: SeekingAlpha at 2017-12-22 08:53:57:000
In January 2016, the biopharmaceutical stocks declined sharply, and the relevant indices did not fully recover for nearly 18 months. In fact, the IBB now stands 5% below the level at which it closed out 2015. As I discussed in my 12/1/2017 article, we are on the verge of another great era in… read more...
Going Out On A Limb: Expectations For Healthcare Stocks In January
via: SeekingAlpha at 2017-12-22 08:53:57:000
In January 2016, the biopharmaceutical stocks declined sharply, and the relevant indices did not fully recover for nearly 18 months. In fact, the IBB now stands 5% below the level at which it closed out 2015. As I discussed in my 12/1/2017 article, we are on the verge of another great era in… read more...
Going Out On A Limb: Expectations For Healthcare Stocks In January
via: SeekingAlpha at 2017-12-22 08:53:57:000
In January 2016, the biopharmaceutical stocks declined sharply, and the relevant indices did not fully recover for nearly 18 months. In fact, the IBB now stands 5% below the level at which it closed out 2015. As I discussed in my 12/1/2017 article, we are on the verge of another great era in… read more...
Going Out On A Limb: Expectations For Healthcare Stocks In January
via: SeekingAlpha at 2017-12-22 08:53:57:000
In January 2016, the biopharmaceutical stocks declined sharply, and the relevant indices did not fully recover for nearly 18 months. In fact, the IBB now stands 5% below the level at which it closed out 2015. As I discussed in my 12/1/2017 article, we are on the verge of another great era in… read more...
Risk-Adjusted Net Present Value For Arbutus Biopharma Corp
via: SeekingAlpha at 2017-12-21 10:38:44:000
I wrote an article on July 19th to estimate the value of ABUS using a rNPV model. This new article is an update of the previous model to incorporate 3Q results. 2Q events were covered in this other article . You can see the first article here , where I explained the model in detail. Aln… read more...
Risk-Adjusted Net Present Value For Arbutus Biopharma Corp
via: SeekingAlpha at 2017-12-21 10:38:44:000
I wrote an article on July 19th to estimate the value of ABUS using a rNPV model. This new article is an update of the previous model to incorporate 3Q results. 2Q events were covered in this other article . You can see the first article here , where I explained the model in detail. Aln… read more...
Risk-Adjusted Net Present Value For Arbutus Biopharma Corp
via: SeekingAlpha at 2017-12-21 10:38:44:000
I wrote an article on July 19th to estimate the value of ABUS using a rNPV model. This new article is an update of the previous model to incorporate 3Q results. 2Q events were covered in this other article . You can see the first article here , where I explained the model in detail. Aln… read more...
Risk-Adjusted Net Present Value For Arbutus Biopharma Corp
via: SeekingAlpha at 2017-12-21 10:38:44:000
I wrote an article on July 19th to estimate the value of ABUS using a rNPV model. This new article is an update of the previous model to incorporate 3Q results. 2Q events were covered in this other article . You can see the first article here , where I explained the model in detail. Aln… read more...
Risk-Adjusted Net Present Value For Arbutus Biopharma Corp
via: SeekingAlpha at 2017-12-21 10:38:44:000
I wrote an article on July 19th to estimate the value of ABUS using a rNPV model. This new article is an update of the previous model to incorporate 3Q results. 2Q events were covered in this other article . You can see the first article here , where I explained the model in detail. Aln… read more...
Nasdaq Biotech Index: 54 to be added, 15 removed
via: SeekingAlpha at 2017-12-11 07:45:08:000
Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...
Nasdaq Biotech Index: 54 to be added, 15 removed
via: SeekingAlpha at 2017-12-11 07:45:08:000
Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...
Nasdaq Biotech Index: 54 to be added, 15 removed
via: SeekingAlpha at 2017-12-11 07:45:08:000
Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...
Nasdaq Biotech Index: 54 to be added, 15 removed
via: SeekingAlpha at 2017-12-11 07:45:08:000
Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...
Nasdaq Biotech Index: 54 to be added, 15 removed
via: SeekingAlpha at 2017-12-11 07:45:08:000
Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...
Medical Stocks: Investing For 2018
via: SeekingAlpha at 2017-12-01 08:40:00:000
2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate … read more...
Medical Stocks: Investing For 2018
via: SeekingAlpha at 2017-12-01 08:40:00:000
2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate … read more...
Medical Stocks: Investing For 2018
via: SeekingAlpha at 2017-12-01 08:40:00:000
2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate … read more...
Medical Stocks: Investing For 2018
via: SeekingAlpha at 2017-12-01 08:40:00:000
2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate … read more...
Medical Stocks: Investing For 2018
via: SeekingAlpha at 2017-12-01 08:40:00:000
2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate … read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
via: SeekingAlpha at 2017-11-21 03:22:06:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens US stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2017. Please visit our Tracking Ole Andreas Halvorsen&#x… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
via: SeekingAlpha at 2017-11-21 03:22:06:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens US stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2017. Please visit our Tracking Ole Andreas Halvorsen&#x… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
via: SeekingAlpha at 2017-11-21 03:22:06:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens US stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2017. Please visit our Tracking Ole Andreas Halvorsen&#x… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
via: SeekingAlpha at 2017-11-21 03:22:06:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens US stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2017. Please visit our Tracking Ole Andreas Halvorsen&#x… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
via: SeekingAlpha at 2017-11-21 03:22:06:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens US stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2017. Please visit our Tracking Ole Andreas Halvorsen&#x… read more...
The Stock Market Cycle And Implications For Medical Stock Investing
via: SeekingAlpha at 2017-11-14 12:48:31:000
Nearly one year ago, I wrote that my target DJIA price for 2017 was 23,000. Furthermore, I stated that this first leg of the bull market would not end until the small and micro cap medical stocks had advanced. Both of these events have occurred. The first leg of this bull market began in 200… read more...
The Stock Market Cycle And Implications For Medical Stock Investing
via: SeekingAlpha at 2017-11-14 12:48:31:000
Nearly one year ago, I wrote that my target DJIA price for 2017 was 23,000. Furthermore, I stated that this first leg of the bull market would not end until the small and micro cap medical stocks had advanced. Both of these events have occurred. The first leg of this bull market began in 200… read more...
The Stock Market Cycle And Implications For Medical Stock Investing
via: SeekingAlpha at 2017-11-14 12:48:31:000
Nearly one year ago, I wrote that my target DJIA price for 2017 was 23,000. Furthermore, I stated that this first leg of the bull market would not end until the small and micro cap medical stocks had advanced. Both of these events have occurred. The first leg of this bull market began in 200… read more...
The Stock Market Cycle And Implications For Medical Stock Investing
via: SeekingAlpha at 2017-11-14 12:48:31:000
Nearly one year ago, I wrote that my target DJIA price for 2017 was 23,000. Furthermore, I stated that this first leg of the bull market would not end until the small and micro cap medical stocks had advanced. Both of these events have occurred. The first leg of this bull market began in 200… read more...
The Stock Market Cycle And Implications For Medical Stock Investing
via: SeekingAlpha at 2017-11-14 12:48:31:000
Nearly one year ago, I wrote that my target DJIA price for 2017 was 23,000. Furthermore, I stated that this first leg of the bull market would not end until the small and micro cap medical stocks had advanced. Both of these events have occurred. The first leg of this bull market began in 200… read more...
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
via: SeekingAlpha at 2017-11-12 03:24:08:000
The bioscience sector is poised with substantial growth and galvanized by promising prospects. One can earn 90% profits in one day, following a positive catalyst event. Stellar companies such as Kite Pharma (NASDAQ: KITE ), Amicus Therapeutics (NASDAQ: FOLD ), Conatus Pharmaceuticals (NASDAQ: … read more...
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
via: SeekingAlpha at 2017-11-12 03:24:08:000
The bioscience sector is poised with substantial growth and galvanized by promising prospects. One can earn 90% profits in one day, following a positive catalyst event. Stellar companies such as Kite Pharma (NASDAQ: KITE ), Amicus Therapeutics (NASDAQ: FOLD ), Conatus Pharmaceuticals (NASDAQ: … read more...
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
via: SeekingAlpha at 2017-11-12 03:24:08:000
The bioscience sector is poised with substantial growth and galvanized by promising prospects. One can earn 90% profits in one day, following a positive catalyst event. Stellar companies such as Kite Pharma (NASDAQ: KITE ), Amicus Therapeutics (NASDAQ: FOLD ), Conatus Pharmaceuticals (NASDAQ: … read more...
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
via: SeekingAlpha at 2017-11-12 03:24:08:000
The bioscience sector is poised with substantial growth and galvanized by promising prospects. One can earn 90% profits in one day, following a positive catalyst event. Stellar companies such as Kite Pharma (NASDAQ: KITE ), Amicus Therapeutics (NASDAQ: FOLD ), Conatus Pharmaceuticals (NASDAQ: … read more...
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
via: SeekingAlpha at 2017-11-12 03:24:08:000
The bioscience sector is poised with substantial growth and galvanized by promising prospects. One can earn 90% profits in one day, following a positive catalyst event. Stellar companies such as Kite Pharma (NASDAQ: KITE ), Amicus Therapeutics (NASDAQ: FOLD ), Conatus Pharmaceuticals (NASDAQ: … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|